The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The importance is on the data and is critical.
There will be know problem with severe adverse events at these doses.
They are on effect 30% of the maximum therapeutic dose stated by Sareum.
Now the good thing is at these levels the therapeutic range has been hit dhich l believe Sareum were pleasantly surprised by.
So we have a Tyk2 Jak 1 inhibitor that has potentially greater efficacy in Psoriasis with what should be a similar safety profile.
In addition to the Tyk2 we have Jak 1 which should prove far better in other Indications that Deucracitinib flunked in.
Deucracitinib was hailed as the be all and end all, based on a very good satisfactory safety profile.
Yes allosteric TyK2 via JH 2 domain which controls the active site JH1.
Marvellous, it ain't that good in Psoriasis and failed to meet either of its end points in Ulcerative Colitus.
Rather like you having your feet on fire and you go pi55ing over the boots of the person standing next to you.
Take a read over at ADzvN at a couple of the mongs who post.
20 year old drug
Sarfum going to collapse.
MHRA refused it due to it being old and even with an established experienced CRO that formulated the capsule it was not considered safe to give to patients.
Fools. Not least the one who claimed he sold at the peak and at the same time claims sareum are so bad and inept.
I think ot bought at a peak and sold at a loss.
The other idiot claims to put valid arguments which he states people on the ADVN cannot give an answer
If they want to pit argument forward here they are welcome to fo so. They have lost in the past.
They then get shirty and insulting which results in a ban. Just take a read at the drivel they put.
Sareum will now go from strength to strength and there is absolutely nothing they can do about it.
More chance of this share going to 800 million market cap than the 8 million prior to complete failure that they forecast.
Have a good weekend all, we are rapidly approaching news time.
Here's to hoping a bidding war over 1801 escalates into an all out takeover melee. I could do with just waking up to a 2 billion offer or something, honestly.
Is that even possible post a phase 1 trial. A few more weeks to go folks. Anyone heard from RMM?
And a very nice fact indeed Basil đź‘Ť
It's the “Patent Cliffs" that investors should be getting excited about. The one to keep an eye on is Stelara, which has annual sales of over $7.5 billion and targets psoriasis, psoriatic arthritis and Crohn’s disease. Its patent appears be expiring in the next 2 years. This is great news for Sareum, as SDC1801 is aimed at psoriasis (& other diseases). It's why many of us have been topping up with more SAR shares at these bargain basement prices over the last few weeks....
Good luck, Brighty
Yes and it's worth pointing out to the uninitiated that BIG gains happen in the pharma sector. We know that because SAR has already gone up x 46 before. That’s a fact.
If the data is positive it will start the firing gun for big pharma to do a licencing deal. At that stage our share price will then rocket.
You only have to see what happened to a similar bombed out share price with Tempest Therapeutics to see what’s possible. They had dropped to an all-time low (just like Sareum) and then positive data was revealed that saw the share price surge by x 39 in 1 week last September. That’s a fact. Have a great weekend.
Level 2 l believe showed buys at 31 and 32p entered at 16.50 and 16.51
Was very interesting that for the last 20 mins of trading with the 'visible' spread at 27-29, I was being quoted 28.9 to sell with AJBells (final quote was at 28.8p)
Such a difference between actual and visble bid is unusual....any theories on what Mms were up to?
There is no reason as to why the results should not be very good.
Indicative so far in the RNS that "potentially no serious adverse events.'
That should give a close a clue as you will get as to the final expectation of results 1a data.
Nice blue sky and nice blue rise, it we still sit very low with regards to SP. Market Cap around 31 million.
Should RF not have any shares left, then a gradual climb north next week should be on the cards.
Regards and a good weekend to all.
To my understanding, there’s a lack of alignment between the sentiment expressed in this video and the timeline & facts documented in the schedule 14A filing which followed the GSK acquisition. I’ll be generous and call it “looking backwards with rose-tinted glasses” :)
Five months ago AZ also paid another small bio, Eccogene, $185m upfront, following encouraging prelim results of Eccogene's Phase I trial of ECC5004. The deal also included up to $1.825bn in future clinical, regulatory plus commercial milestones and tiered royalties on product sales. That would do nicely! i.e. AZ (Or ANother such as GSK or J&J) could swoop in with a licencing deal for SDC-1801 if the preliminary results are good. The clock is ticking.
Hi Bailiff - always difficult to judge exactly which way the sp will move on any given day. With the repeated NT responses early this morning I was surprised they held the price back as long as they did before increasing it. Needless to say my final purchase was pretty much at the top; hey ho, what's a couple of pence either way at these prices when the potential upside is so large?
Regards.
A reminder everyone that in 2023 AZ paid an upfront payment of $63m for KYM Bio's Phase I clinical candidate CMG901 and agreed additional milestone development and sales-related payments of up to $1.1bn. It's what we are all here for with SDC-1801, SRA-737 and SDC-1802. i.e. Big pharma pay big bucks for P1 candidates. Sareum's SDC-1801 could be next.
@hbd. Just back from spreading the love and see price hasn’t really changed from when I last looked. My £10k purchase wasn’t filled so cancelled it. I wonder if I will rue that decision????? Just felt the rise wasn’t going to be sustained but have been wrong before about Sar! Gla and have a good weekend all x
Of course it doesn't make sense. That's the point. Obfuscation.
Why would the mm’s raise the price just so one shareholder can offload? It doesn’t make sense. It’s just supply and demand.
Hopefully, the engineered rise earlier successfully cleared more RF shares/warrants.
We had this a week ago....an unexpected rise and increase in volume. Hopefully its not like last time just to facilitate RF getting shot of more shares at a better price
Dont get me wrong, always happy to see a rise, but its already coming off the boil
Whst news would that be then?
Imminent news if 1801 trial results?
IMO we need news for a sustained rise, other wise its going to be ups and downs.
Tickled
Yeah SOG, just bought another ÂŁ9k at 29.37p
This is Nice to see another rise :O)
30p buy coming up soon too.
Should hit 29p buy soon!
Hi Bailiff - I'm also with the Halifax but I don't use the order system as I'd rather see the price I'm paying before pulling the trigger.